FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Private Issuer
Pursuant to Rule 13s - 16 or 15d - 16 of
the Securities Exchange Act of 1934
For the month of February 2006
Acambis plc
(Translation of registrant's name into English)
Peterhouse Technology Park
100 Fulbourn Road
Cambridge CB1 9PT
England
(address of principal executive offices)
(Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F
Forms 20-F X Form 40-F
Indicate by check mark whether the registrant by furnishing the information
contained in this Form also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934).
Yes No X
(if "Yes" is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g3-2(b): 82- ).
Enclosure: Fellner joins Acambis Board
Acambis appoints Peter Fellner as Non-executive Director
Cambridge, UK and Cambridge, Massachusetts - 7 February 2006 - Acambis plc
(Acambis) (LSE: ACM, NASDAQ: ACAM) has appointed Peter Fellner to its Board of
Directors as a Non-executive Director with immediate effect.
Dr Fellner led the development of Celltech Group plc (Celltech) from a small
research company into the UK's leading biotechnology company. He was Celltech's
Chief Executive Officer from 1990 to 2003 and Chairman from 2003 until its
acquisition by the Belgian biopharmaceutical company, UCB SA, in 2004.
Dr Fellner continues to have a strong involvement in the industry through
several board positions. He is Chairman of Vernalis plc and Astex Therapeutics
Limited, a director of UCB SA, and a non-executive director of Evotec AG and
Bespak plc. He is also a director of one of Europe's largest technology
companies, QinetiQ Group plc. In addition, he is a director of Oxford
University's technology transfer group, Isis Innovation Limited, and a member
of the UK's Medical Research Council.
Before Celltech, he was Chief Executive Officer of Roche UK from 1986 to 1990,
having previously been Director of Roche UK Research Centre from 1984 to 1986.
From 1980 to 1984 he served as a Director of Research at Searle UK.
Alan Smith, Chairman of Acambis, commented:
"Peter Fellner is one of the leading figures in the UK biotechnology industry
and we are delighted to welcome him to our Board. With his extensive knowledge
and experience, we believe his insight and advice will be invaluable as we
oversee the continued development of Acambis."
Acambis confirms that no information is disclosable in relation to the
appointment of Peter Fellner pursuant to the requirements of Listing Rule 9.6.13
paragraphs (1) to (6).
-ends-
Enquiries:
Acambis plc
Gordon Cameron, Chief Executive Officer: Tel +1 (617) 761 4200
Lyndsay Wright, VP, Communications and IR: Tel +44 (0) 1223 275 300
Financial Dynamics
David Yates/Lucy Briggs: Tel +44 (0) 20 7831 3113
About Acambis
Acambis is a leading developer of vaccines to prevent and treat infectious
diseases. Recognised internationally as the leading producer of smallpox
vaccines, Acambis is developing an investigational smallpox vaccine, ACAM2000,
and is manufacturing emergency-use stockpiles of this investigational vaccine
for the US Government and other governments around the world. It is also
developing an attenuated smallpox vaccine, MVA3000, under contracts with the US
National Institutes of Health. Acambis is establishing a travel vaccines
franchise through its US-based subsidiary Berna Products Corporation, which
markets Vivotif(R), the world's only licensed oral typhoid vaccine, in North
America. Acambis has other potential travel vaccines in development and is also
developing an investigational vaccine against the West Nile virus, which has
spread to 48 US States in the last six years.
Acambis is based in Cambridge, UK and Cambridge, Massachusetts, US. Its primary
listing is on the London Stock Exchange (ACM) and its shares are listed in the
form of American Depositary Receipts on NASDAQ (ACAM). More information is
available at www.acambis.com.
"Safe Harbor" statement under the Private Securities Litigation Reform Act of
1995:
The statements in this news release that are not historical facts are
forward-looking statements that involve risks and uncertainties, including the
timing and results of clinical trials, product development, manufacturing and
commercialisation risks, the risks of satisfying the regulatory approval process
in a timely manner, the need for and the availability of additional capital. For
a discussion of these and other risks and uncertainties see "Risk management" in
the Company's 2004 Annual Report and "Risk factors" in its Form 20-F, in
addition to those detailed on the Company's website and in the Company's filings
made with the Securities and Exchange Commission from time to time. These
forward-looking statements are based on estimates and assumptions made by the
management of Acambis and are believed to be reasonable, though are inherently
uncertain and difficult to predict. Actual results or experience could differ
materially from the forward-looking statements.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant Peptide Therapeutics Group has duly caused this report to be
signed on its behalf by the undersigned, thereunto duly authorized.
Date: 07 February 2006 ACAMBIS PLC
By: /s/ Lyndsay Wright
Name: Lyndsay Wright
Title: VP, Communications and IR.